Floatz logo

ROPIVACAINE

Recurrent Multiple Myeloma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Recurrent Multiple Myeloma cohort.

Asset / SponsorPhaseRating
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 2B
FLAVONE, 3,3',4',5,7-PENTAHYDROXY-
Mayo Clinic
Phase 2CCC
Infliximab
Naresh Bumma
Phase 2CCC
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells
Elvira Umyarova
Phase 1CC
Pevonedistat
National Cancer Institute (NCI)
Phase 1CC

View all 11 →

Same molecule, other indications

ROPIVACAINE is also rated in:

post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →
Knee Pain ChronicDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritis, hipDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →